28.02

0.57% 0.16

Acadia Pharmaceuticals Inc (ACAD)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ACAD? Forum Prognose

Schlusskurs vom Vortag:

$27.86

Offen:

$27.77

24-Stunden-Volumen:

1.68M

Relative Volume:

1.04

Marktkapitalisierung:

$4.83B

Einnahmen:

$1.10B

Nettoeinkommen (Verlust:

$375.65M

KGV:

12.76

EPS:

2.1963

Netto-Cashflow:

$113.59M

1W Leistung:

-3.74%

1M Leistung:

+3.20%

6M Leistung:

+19.79%

1J Leistung:

+9.88%

1-Tages-Spanne:

$27.65

$28.19

1-Wochen-Bereich:

$27.61

$29.75

52-Wochen-Spanne:

$19.69

$30.96

Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile

Firmenname

Acadia Pharmaceuticals Inc

Sektor

Healthcare (1074)

Branche

Biotechnology (600)

Telefon

858-558-2871

Adresse

12830 EL CAMINO REAL, SAN DIEGO

Mitarbeiter

798

Twitter

@acadiapharma

Nächster Verdiensttermin

2026-08-04

Neueste SEC-Einreichungen

ACAD's Discussions on Twitter

Compare ACAD vs VRTX, REGN, ARGX, MRNA, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ACAD Acadia Pharmaceuticals Inc	28.02	5.00B	1.10B	375.65M	113.59M	2.1963
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-25	Hochstufung	BofA Securities	Neutral → Buy
2026-02-24	Eingeleitet	Wolfe Research	Outperform
2026-02-23	Hochstufung	Mizuho	Neutral → Outperform
2025-10-21	Eingeleitet	Citigroup	Buy
2025-05-21	Hochstufung	Deutsche Bank	Hold → Buy
2025-02-11	Eingeleitet	Deutsche Bank	Hold
2025-01-03	Herabstufung	Guggenheim	Buy → Neutral
2024-10-10	Fortgesetzt	Raymond James	Mkt Perform
2024-08-07	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2024-06-27	Eingeleitet	BMO Capital Markets	Outperform
2024-03-12	Herabstufung	Mizuho	Buy → Neutral
2024-03-12	Bestätigt	Needham	Buy
2024-01-30	Eingeleitet	Robert W. Baird	Outperform
2024-01-24	Hochstufung	Needham	Hold → Buy
2023-12-19	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2023-12-14	Herabstufung	Deutsche Bank	Buy → Hold
2023-12-13	Eingeleitet	Citigroup	Buy
2023-12-12	Eingeleitet	Deutsche Bank	Buy
2023-11-06	Hochstufung	Mizuho	Neutral → Buy
2023-10-17	Eingeleitet	UBS	Buy
2023-10-10	Hochstufung	JP Morgan	Neutral → Overweight
2023-01-03	Hochstufung	Guggenheim	Neutral → Buy
2022-11-04	Herabstufung	Goldman	Neutral → Sell
2022-11-01	Eingeleitet	Loop Capital	Hold
2022-08-08	Herabstufung	Citigroup	Buy → Neutral
2022-08-05	Herabstufung	Citigroup	Buy → Neutral
2022-06-21	Herabstufung	Jefferies	Buy → Underperform
2022-06-16	Hochstufung	Jefferies	Hold → Buy
2022-03-16	Hochstufung	Canaccord Genuity	Hold → Buy
2022-02-09	Hochstufung	H.C. Wainwright	Neutral → Buy
2022-01-05	Hochstufung	Citigroup	Neutral → Buy
2021-12-21	Herabstufung	Guggenheim	Buy → Neutral
2021-11-01	Hochstufung	Guggenheim	Neutral → Buy
2021-10-14	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2021-09-23	Fortgesetzt	Needham	Hold
2021-06-10	Eingeleitet	Berenberg	Hold
2021-04-07	Herabstufung	H.C. Wainwright	Buy → Neutral
2021-04-06	Herabstufung	Canaccord Genuity	Buy → Hold
2021-04-06	Herabstufung	Goldman	Buy → Neutral
2021-04-06	Herabstufung	Jefferies	Buy → Hold
2021-04-06	Herabstufung	Mizuho	Buy → Neutral
2021-04-05	Herabstufung	Raymond James	Outperform → Mkt Perform
2021-03-10	Herabstufung	BofA Securities	Buy → Neutral
2021-03-09	Herabstufung	Citigroup	Buy → Neutral
2021-03-09	Herabstufung	Guggenheim	Buy → Neutral
2021-03-09	Bestätigt	H.C. Wainwright	Buy
2021-03-09	Herabstufung	Raymond James	Strong Buy → Outperform
2021-03-09	Herabstufung	Stifel	Buy → Hold
2020-12-16	Eingeleitet	Mizuho	Buy
2020-11-16	Hochstufung	Raymond James	Outperform → Strong Buy
2020-08-25	Eingeleitet	Raymond James	Outperform
2020-08-20	Eingeleitet	Morgan Stanley	Overweight
2020-07-07	Hochstufung	Stifel	Hold → Buy
2020-04-16	Eingeleitet	Jefferies	Buy
2020-03-31	Hochstufung	Goldman	Neutral → Buy
2020-03-06	Eingeleitet	Citigroup	Buy
2019-12-16	Eingeleitet	Guggenheim	Buy
2019-10-24	Eingeleitet	Oppenheimer	Perform
2019-10-01	Eingeleitet	RBC Capital Mkts	Outperform
2019-09-13	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2019-09-10	Hochstufung	Canaccord Genuity	Hold → Buy
2019-07-23	Bestätigt	Needham	Buy
2018-12-10	Eingeleitet	Canaccord Genuity	Hold
2018-09-21	Hochstufung	Piper Jaffray	Neutral → Overweight
2018-08-09	Bestätigt	Stifel	Hold
2018-08-07	Eingeleitet	Stifel	Hold
2018-08-06	Herabstufung	Piper Jaffray	Overweight → Neutral
2017-10-06	Fortgesetzt	Goldman	Neutral

Alle ansehen

Acadia Pharmaceuticals Inc Aktie (ACAD) Neueste Nachrichten

Aug 21, 2026

Virtus Advisers LLC Makes New Investment in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat

Aug 21, 2026

Great Lakes Advisors LLC Purchases New Holdings in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat

Aug 21, 2026

Aug 18, 2026

ACADIA Pharmaceuticals (NASDAQ:ACAD) Hits Fresh High - Kalkine Media

Aug 18, 2026

ACADIA Pharmaceuticals (NASDAQ:ACAD) Hits New 1-Year HighHere's What Happened - MarketBeat

Aug 18, 2026

Rice Hall James & Associates LLC Purchases Shares of 618,887 ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat

Aug 18, 2026

Stronger 2026 Outlook After Mixed Q2 Results Might Change The Case For Investing In ACAD (ACAD) - simplywall.st

Aug 18, 2026

Aug 17, 2026

UBS raises Acadia Pharmaceuticals stock price target on trial optimism By Investing.com - Investing.com Australia

Aug 17, 2026

ACAD Maintained by UBS -- Price Target Raised to $49.00 - GuruFocus

Aug 17, 2026

UBS raises Acadia Pharmaceuticals stock price target on trial optimism - Investing.com

Aug 17, 2026

GSA Capital Partners LLP Makes New Investment in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat

Aug 17, 2026

Empowered Funds LLC Makes New Investment in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat

Aug 17, 2026

Aug 16, 2026

ACAD Stock Eyes Best Day In Over A Year As CHMP Recommends Approval For Rare Nerve Disorder Drug In Europe - Stocktwits

Aug 16, 2026

48,794 Shares in ACADIA Pharmaceuticals Inc. $ACAD Purchased by State of Wyoming - MarketBeat

Aug 16, 2026

Assenagon Asset Management S.A. Sells 57,075 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat

Aug 16, 2026

Aug 15, 2026

Bank of America Corp DE Acquires 332,325 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat

Aug 15, 2026

ACADIA Pharmaceuticals Inc. Stock 12‑Month Price Target Cut to $33.05, Implies 17% Upside - TradingView

Aug 15, 2026

Aug 14, 2026

Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts - Stocktwits

Aug 14, 2026

Aug 13, 2026

STATE STREET CORP Adds to ACADIA Pharmaceuticals Inc (ACAD) Stak - GuruFocus

Aug 13, 2026